Clinical Trial Update: Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating remission of Type 2 Diabetes mellitus with metabolic intervention using IGlarLixi.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• iGlarLixi (insulin glargine + lixisenatide)

Snippet

Sponsor: Population Health Research Institute | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED